124 related articles for article (PubMed ID: 23539641)
1. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
Ratti E; Bettica P; Alexander R; Archer G; Carpenter D; Evoniuk G; Gomeni R; Lawson E; Lopez M; Millns H; Rabiner EA; Trist D; Trower M; Zamuner S; Krishnan R; Fava M
J Psychopharmacol; 2013 May; 27(5):424-34. PubMed ID: 23539641
[TBL] [Abstract][Full Text] [Related]
2. Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.
Vincenzi B; Trower M; Duggal A; Guglielmini P; Harris P; Jackson D; Lacouture ME; Ratti E; Tonini G; Wood A; Ständer S
BMJ Open; 2020 Feb; 10(2):e030114. PubMed ID: 32034016
[TBL] [Abstract][Full Text] [Related]
3. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
4. Brain neurokinin-1 receptor availability in never-medicated patients with major depression - A pilot study.
Nyman M; Eskola O; Kajander J; Jokinen R; Penttinen J; Karjalainen T; Nummenmaa L; Hirvonen J; Burns D; Hargreaves R; Solin O; Hietala J
J Affect Disord; 2019 Jan; 242():188-194. PubMed ID: 30193189
[TBL] [Abstract][Full Text] [Related]
5. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
Ratti E; Bellew K; Bettica P; Bryson H; Zamuner S; Archer G; Squassante L; Bye A; Trist D; Krishnan KR; Fernandes S
J Clin Psychopharmacol; 2011 Dec; 31(6):727-33. PubMed ID: 22020354
[TBL] [Abstract][Full Text] [Related]
6. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).
Smith J; Allman D; Badri H; Miller R; Morris J; Satia I; Wood A; K Trower M
Chest; 2020 Jan; 157(1):111-118. PubMed ID: 31421110
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
Werner FM; Coveñas R
Curr Pharm Des; 2019; 25(4):388-395. PubMed ID: 30969164
[TBL] [Abstract][Full Text] [Related]
8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.
Trower MK; Fisher A; Upton N; Ratti E
Exp Dermatol; 2014 Nov; 23(11):858-60. PubMed ID: 25078633
[TBL] [Abstract][Full Text] [Related]
10. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
[TBL] [Abstract][Full Text] [Related]
12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Kramer MS; Winokur A; Kelsey J; Preskorn SH; Rothschild AJ; Snavely D; Ghosh K; Ball WA; Reines SA; Munjack D; Apter JT; Cunningham L; Kling M; Bari M; Getson A; Lee Y
Neuropsychopharmacology; 2004 Feb; 29(2):385-92. PubMed ID: 14666114
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
16. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
Michelson D; Hargreaves R; Alexander R; Ceesay P; Hietala J; Lines C; Reines S
Int J Neuropsychopharmacol; 2013 Feb; 16(1):1-11. PubMed ID: 22433185
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
[TBL] [Abstract][Full Text] [Related]
19. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
20. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
